Universal empirical antifungal therapy (EAT) in patients with unexplained persistent febrile neutropenia (PFN) is the standard of care, but EAT could be applied in selected patients on the basis of clinical criteria and risk factors. A prospective interventional study was carried out to analyse the incidence and related mortality of invasive fungal infection (IFI) in patients with PFN according to whether or not EAT was indicated. EAT was indicated according to the following criteria: (a) severe sepsis or septic shock; (b) focused infection: lung, central nervous system, sinus, abdominal or skin; (c) individualized clinical decision in patients at high risk. Sixty-six (19%) of 347 episodes of febrile neutropenia fulfilled PFN criteria, 97% with a haematological malignancy. Just 26 (39.4%) were treated with EAT. The overall IFI incidence was 4.5%. In the group that received EAT, three patients developed IFI (11.5%), in comparison with none in the group that did not receive it (P ¼ 0.04, RR 2.7:1.9-3.8). IFI-related mortality was null in the group that did not receive EAT and 8% (two of 26 patients) in the group that received EAT. These data suggest that in patients with PFN, EAT in selected patients may be safe and avoid unnecessary antifungal therapy.
Introduction
In spite of the advances in the diagnosis and treatment, invasive fungal infections (IFI) are the main cause of mortality in patients with haematological malignancies during post-chemotherapy neutropenia and after allohaematopoietic (H) SCT. The Infectious Diseases Society of America recommends empirical antifungal therapy (EAT) in neutropenic patients with persistent fever without aetiological diagnosis after 96 h of correct empirical antimicrobial therapy (B-II), 1 with the main objective of improving the outcome of IFI by prompt therapy.
Although these recommendations have been the standard approach over the last two decades, to date no study has shown unequivocally that EAT is better than a placebo at reducing the incidence or related mortality of IFI. 2, 3 Furthermore, universal EAT is so inefficient that in order to cure 1.8 IFI episodes, it is necessary to treat 100 patients, 4 and its use is not exempt from adverse effects, additional cost and antifungal resistance selection. 5, 6, 7 For these reasons, universal EAT has been called into question. 4, 8, 9, 10 Recent studies suggest that the restricted use of EAT is not associated with an increase in IFI-related mortality, 8 but the impact of this approach in patients with persistent febrile neutropenia (PFN) has not been studied and the selection criteria for patients to benefit from receiving EAT have not been clearly defined. Cisneros et al. 4 have proposed selection criteria based on risk factors and directed by clinical criteria. Thus, the more common IFI in neutropenic patients are pneumonia, rhinosinusitis and brain abscess caused by Aspergillus spp. and invasive candidiasis (candidemia and hepatoesplenic candidiasis). 6, 7, 11, 12 Otherwise, patients at highest risk of IFI are allo-HSCT recipients and patients with myeloblastic leukaemia in relapse. 6, 7 Thus, EAT was indicated according to the following criteria: (a) In all patients with severe sepsis or septic shock; (b) In all patients, a focal infection suggestive of IFI; In the rest of the patients, ETA was not indicated at first and further diagnostic evaluation was performed. In patients at high risk without diagnosis after complete diagnostic evaluation and persistent fever, EAT was also indicated after an individualized clinical decision.
The aim of this study is to investigate the indication of EAT exclusively in patients with febrile neutropenia who were selected according to risk factors and clinical criteria, 4 as well as its impact on incidence and IFI-related mortality.
Materials and methods
Design and study population This is a prospective interventional study of every febrile neutropenia episode in patients aged 16 Invasive fungal infection attributable mortality was defined as death after the diagnosis of IFI with refractory disease (progression or fail to improve), in the absence of other condition believed to cause death.
Initial evaluation and antimicrobial prophylaxis and therapy
Initial evaluation of febrile episode in every patient included a complete physical examination and the following tests: chest X-ray performed in the first 24 h after the fever set up, and repeated if the fever persisted or if respiratory symptoms appeared. Blood cultures were obtained from all patients at the onset of fever and repeated in 72 h if results were negative. Thin-section thoracic computed scan was performed on all patients with abnormal chest X-ray or respiratory symptoms and normal chest X-ray. Bronchoscopy was performed, when clinically possible, on patients with pulmonary infiltrates. Abdominal ultrasound and/or abdominal computed scan were performed on patients with abdominal pain (patients with painful hepatomegaly and/or elevated serum phosphatase alkaline in which hepatoesplenic candidiasis was suspected or suspicion of necrotizing enterocolitis without response to support and antibacterial therapy, to rule out local complications and support diagnosis). Additional blood, sputum and samples from infected sites were cultured as clinically indicated. Galactomannan Ag detection in serum was not available in our centre during the study period.
Primary antifungal prophylaxis with fluconazole 200-400 mg orally daily was used only in allo-SCT recipients.
Antibacterial therapy was initiated in every patient at the onset of fever, after obtaining blood cultures, with an antipseudomonal b-lactam with or without aminoglycoside. A glycopeptide was added when indicated according to published guidelines. 1 Evaluation and management of persistent febrile neutropenia episodes The first step was to evaluate the severity of the episode (presence of severe sepsis or septic shock) ( Table 1 ). The second step was the identification of any infectious foci susceptible to be produced by fungi. EAT was indicated according to the following clinical criteria: (a) In all patients with severe sepsis or septic shock; (b) In all patients with any of the following foci of infection: lung, central nervous system, sinus, abdominal or skin.
In patients with neither severity signs nor infectious foci, EAT was not indicated and further diagnostic tests were performed: Thin-section thoracic computed scan initially and if respiratory symptoms or signs appeared, abdominal ultrasound and repeated blood cultures. When fever persisted without an alternative diagnosis and without clinical deterioration, EAT was indicated after an individualized clinical decision made by the physician in patients at high risk (acute leukaemia and allo-SCT recipients). 6, 7 Liposomal or conventional amphotericin (3-5 mg/kg/day and 0.7-1.5 mg/kg/day, respectively) or voriconazole (6 mg/ kg/day and 4 mg/kg/day on the following days) were used for EAT according to the most probable fungal aetiology in each case.
Statistical analysis
A comparative analysis of infectious aetiologies, with an incidence of proven and probable IFI and IFI-related mortality between patients who received antifungal empirical therapy and patients who did not, was performed. As galactomannan test was not performed during the study period, we also analyse the incidence of possible IFI and possible IFI-related mortality. A subanalysis of incidence of proven and probable IFI and IFI-related mortality including only IFI high-risk patients (acute leukaemia and allo-TPH recipients) was also performed.
The data were expressed as means ( ± s.d.) for normally distributed data or as medians (and range) for nonnormally distributed data. The w 2 or Fisher's exact test were used to compare the categorical data among the groups. Student's t-test was performed for comparison of means and the Mann-Whitney U-test was performed when appropriate. A P-value o0.05 was considered to be statistically significant. The statistical analysis was performed with software from the Statistical Package for the Social Sciences (SPSS) version 14.
Results

Series description
Three hundred and forty-seven episodes of febrile neutropenia were included. Among them, 66 (19%) fulfilled PFN criteria. The characteristics of the study population are shown in Table 2 .
Persistent febrile neutropenia episodes
The patients were profoundly neutropenic in most of the cases (n ¼ 57, 86.5%), and the median duration of neutropenia was 12 days (6-40). The median duration of the episode of fever was 8 days (6-34). The median duration of neutropenia and fever was different for patients who received EAT (17 and 9 days, respectively) compared with that for those who did not (median of 12 and 7 days, respectively) (P ¼ 0.01 and P ¼ 0.02, respectively).
In 26 episodes (39.4%), the patient received EAT during the PFN episode. The empirical antifungal drugs used were amphotericin (n ¼ 14, 54%), voriconazole (n ¼ 6, 23%), other azoles (n ¼ 5, 19%) and caspofungin (n ¼ 1, 4%). The median duration of treatment was 7 days (1-25). In the remaining 42 episodes of PFN (60.6%), EAT was not indicated. The characteristics of both groups of patients are shown in Table 3 .
The criteria for EAT indication were: (a) septic shock or severe sepsis (nine patients, 34.6%); (b) fever with defined infectious foci (eight patients, 30.7%) as follows: pulmonary (five patients), abdominal (one patient), skin lesions (one patient) and sinusitis (one patient); and (c) individualized clinical decision (nine patients, 34.6%). The median time for starting antifungal therapy, counting from the first day of fever, was 7.5 days (4-19 days). No significant differences in median time to start antifungal therapy according to indication were seen.
IFI incidence
The overall incidence of proven/probable IFI in patients with PFN was 4.5%. In the group that received EAT, three (11.5%) patients developed IFI, in comparison with none in the group that did not receive it (P ¼ 0.04, RR 2.7:1.9-3.8). All the three episodes were caused by moulds, and was the first episode of mould IFI for each patient. The three episodes occurred separately during the study period. The description of the three IFI is detailed in Table 4 .
Also considering possible IFI episodes, the overall IFI incidence was 9%. Every possible IFI episode occurred in the group that received EAT, and in this group the possible/probable/proven IFI incidence was 23%.
Considering only IFI high-risk patients, the overall IFI incidence was 14% (n ¼ 5 episodes in 35 patients) and the probable/proven IFI incidence was 5.7% (n ¼ 2 episodes in 35 patients).
Mortality
The 30-day crude mortality after the onset of fever and neutropenia was 15.1% (10 of 66 patients), and it was higher in the group that received EAT (eight patients, 31%) compared with the group that did not (two out of 40 patients, 5%) (P ¼ 0.03; RR 2:1.2-3.4). Considering only IFI high-risk patients, the 30-day crude mortality after the onset of fever and neutropenia was 17.1% (six of 35 patients).
We analysed the delay for starting antifungal therapy in the eight patients who received EAT and died. In two of Selected antifungal therapy in febrile neutropenia M Aguilar-Guisado et al them, death was related to uncontrolled haematological malignancy. In the rest of the six patients, the median delay was 5.6 days, and every patient with probable or proven IFI in this group received EAT within the first 6 days of fever onset. Two necropsies were performed (20% of deaths), both in the group that received EAT.
The attributable IFI mortality was null in the group that did not receive EAT, and 8% (two out of 26 patients) in the group that received EAT. In the subanalysis of high-risk patients, IFI attributable mortality was 5.7% (two of 35 patients). There was no case of possible IFI attributable mortality.
The first patient was a 44-year-old woman in her fourth month after an allo-SCT, receiving chronic GVHD therapy with steroids and cyclosporin. She was admitted for fever and neutropenia, and 6 days later developed respiratory symptoms, and the thin-section scan of the thorax showed nodules with a halo sign in the right lower lobe. She received antifungal therapy from the fifth day of the onset of fever with amphotericin followed by voriconazole but developed respiratory insufficiency and died 7 days later without recovering from neutropenia. The second patient was a 26-year-old man diagnosed with AML on induction chemotherapy. He started developing fever during neutropenia post-chemotherapy and 6 days later developed cough, thoracic pain, cephalea and facial pain. Voriconazole was started on the sixth day of fever, but he worsened quickly and died 3 days later. Scedosporium prolificans growth in blood cultures and necropsy were performed showing disseminated IFI.
Discussion
In this prospective study, we report the incidence of IFI and IFI-related mortality in patients with PFN after the application of EAT in selected patients instead of the standard universal EAT. The IFI incidence in 40 patients without indication for EAT was null. Furthermore, the application of selected EAT did not determine an increase in IFI-related mortality. Other authors have reported similar results of different approaches to PFN, using restrictive EAT 8 or preemptive approaches. 9 Universal application of EAT in every patient with PFN may be disproportionate for the real incidence of IFI in this population. In our study, 19% of patients with febrile neutropenia developed persistent fever and would have received EAT with such an approach. Nevertheless, only six of these patients (1.7%) developed an IFI, including possible episodes. EAT was indicated in 39% of patients with persistent fever, which means that 61% of nonnecessary EAT was spared. Our results suggest that EAT indication based on risk factors and clinical criteria is a safe Table 3 Characteristics of patients that received empirical antifungal therapy compared with those that did not receive empirical antifungal therapy
Characteristic
Patients that received EAT (n ¼ 26)
Patients that did not receive EAT (n ¼ 40) In this study, global incidence of IFI was 9%, including possible episodes, which is similar to other studies in which galactomannan test was not routinely performed and that jointly reported an IFI incidence of 5.8-9.7% considering both basal and breakthrough IFI. [5] [6] [7] 13 Maertens et al.
9
reported a higher incidence when using daily galactomannan test for IFI screening diagnosis (13%) in a high-risk population. In our study, IFI incidence in a high-risk population was similar (14%, including possible episodes), but in this respect, primary antifungal prophylaxis with activity against moulds was not used in our study, as in Maertens et al.'s study.
Crude global mortality in our study was 15% at 30 days after PFN onset, higher than reported in the previous series (7, 9 and 9%), but in which follow-up was considerably shorter, 14, 17 and 20 days, respectively, 5-7 making comparison difficult. Although the overall mortality of 31% in those patients receiving antifungals was significantly higher compared with 5% in the group that did not receive EAT, these differences in the mortality rate do not seem to be explained by a significant delay for performing the diagnostic evaluation. In fact, results of the different diagnostic investigations (high-resolution computed tomography scan, abdominal ultrasound, bronchoalveolar lavage and fungal stains of different samples) were available within 24 h. Moreover, we have analysed the delay in starting antifungal therapy in patients who received EAT and died, and most of them (including all patients with proven/probable IFI) received antifungal therapy within the first 6 days of fever. The differences in mortality rate are probably explained by other reasons such as more allo-TPH recipients and more patients with acute leukaemia in this group, longer median duration of neutropenia and, in short, more vulnerable patients in the group of patients receiving EAT.
Empirical antifungal therapy in selected patients is based on the fact that unexplained PFN is a complex syndrome with a wide range of infectious and non-infectious aetiologies, different clinical features and variable IFI risk. Pulmonary infiltrates, sinusitis and brain abscess caused by Aspergillus spp. and hepatoesplenic candidiasis are the more common causes of IFI in neutropenic patients. 6, 7, 11, 12 In our study, the three patients with proven or probable IFI had a focal sign of infection (pulmonary infiltrates and/or sinusitis).
On this basis, we proposed a diagnostic and therapeutic approach guided by clinical features. 4 The application of EAT is indicated without delay in patients with severe sepsis or septic shock, or in those with signs of focal infection (pulmonary infiltrates, sinusitis, brain abscess, skin lesions and abdominal focus) in which IFI is an outstanding aetiology. [14] [15] [16] [17] [18] [19] [20] [21] In those patients at high risk for fungal infection, when fever and neutropenia persists without an alternative diagnosis, EAT may be indicated through an individualized clinical decision. In the rest of the patients with asymptomatic fever who are clinically stable (which constituted the main clinical syndrome of PFN) with a low IFI incidence (null in our study), EAT would not be applied and further diagnostic evaluation, including high-resolution thorax scan, galactomannan and abdominal ultrasound, should be performed to establish the aetiology of the persistent fever.
Our prospective study has some weaknesses. The first is that it is a case series from a single centre, so we realize that to correctly evaluate the results obtained, comparison with other series is mandatory. A larger, comparative and multiinstitutional study is needed for further evaluation of the impact. Nevertheless, our results and those from other studies, 8, 9 despite having different methodologies, are along the same lines toward the trend of reducing empirical overtreatment with antifungals in PFN, encouraging the development of new studies in this way. The second weakness is that the galactomannan test was not available for AI diagnosis, which may have determined a lower incidence of IFI. On the basis of its utility in the prompt diagnosis of IFI, 9, 11, 13 this test should be included routinely in patients with PFN. Otherwise, we realize that this approach of EAT indication cannot be extended to nonneutropenic high-risk haematology patients (specially allogeneic haematopoietic stem cell transplant recipients treated for GVHD), which may develop IFI in the absence of fever.
In summary, our data suggest that EAT in selected patients on the basis of clinical criteria and risk factors, instead of universal EAT, may be effective and safe in the management of patients with persistent fever and neutropenia and may avoid overtreatment. Nevertheless, this conclusion may be clarified by the absence of galactomannan monitoring that could misdiagnose probable IFI episodes. Although possible IFI episodes were even included, there was no significant delay in starting EAT compared with the standard approach. New studies based on the application of this approach are needed to test these results.
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